Adjusted earnings reached $2.11 per share, comfortably beating the $1.91 estimate projected by Wall Street analysts. While revenue grew 8.3% to $6.55 billion, the figure fell slightly short of the $6.56 billion consensus. Despite the marginal miss on top-line revenue, the company’s performance in the life-sciences and diagnostics sectors remains robust.

Looking toward the end of the year, the Washington-based firm anticipates core revenue growth between 4% and 5%, excluding respiratory-related income. Investor confidence received a further boost as the company lifted its 2026 adjusted earnings guidance to a range of $8.57 to $8.62 per share, up from the previous forecast of $8.45 to $8.60.